View all CPC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These activites are not approved for AMA PRA Category 1 Credit™.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie; Astellas; AstraZeneca; Exelixis, Inc; Ferring Pharmaceuticals, Inc; Genomic Health, Inc; Medivation, Inc, a Pfizer Company; and Merck Sharp & Dohme Corp.


Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary Malignancies PER Pulse™ Recap

PER Pulse Recap

PER Pulse™ Recap


1 of 3
PER Pulse™ Recap

Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies is an online educational activity that features a series of short video interviews with expert faculty, who address a variety of questions commonly faced by practicing urologists and oncologists via discussion of clinical vignettes that were presented at the live congress. The online activity features discussion on:

  • Metastatic, post-platinum urothelial cancer, by Daniel Petrylak, MD
  • Metastatic renal cell carcinoma after tyrosine kinase inhibitor failure, by David Quinn, MD, MBBS, PhD
  • Early prostate cancer, by Leonard Gomella, MD
  • Prostate cancer with high prostate-specific-antigen level and involvement of retroperitoneal and periaortic lymph nodes, by Leonard Gomella, MD
  • Metastatic castration-resistant prostate cancer, by Daniel Petrylak, MD

Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This first of 3 PER Pulse™ Recaps summarizing the online program focuses on interviews with Dr. Petrylak, during which he discussed:

  • His approach toward a 72-year-old female who had a history of myocardial infarction, hypertension, and obesity, as well as metastatic bladder cancer that had progressed 8 months after completion of gemcitabine/cisplatin therapy
  • Clinical landscape regarding biomarkers in bladder cancer:
    • Mutational burden and bladder cancer subtype are promising biomarkers.
    • PD-L1 status alone is not sufficient to predict response.
  • Trials of checkpoint inhibition therapy plus radiation therapy in the upfront setting that aim to exploit the abscopal effect
  • Lack of standard treatment for patients with high-risk bladder cancer who have received neoadjuvant chemotherapy; checkpoint inhibitory therapy is being investigated in the adjuvant setting for these patients.

2 of 3
PER Pulse™ Recap

Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies is an online educational activity that features a series of short video interviews with expert faculty, who address a variety of questions commonly faced by practicing urologists and oncologists via discussion of clinical vignettes that were presented at the live congress. The online activity features discussion on:

  • Metastatic, post-platinum urothelial cancer, by Daniel Petrylak, MD
  • Metastatic renal cell carcinoma (RCC) after tyrosine kinase inhibitor (TKI) failure, by David Quinn, MD, MBBS, PhD
  • Early prostate cancer, by Leonard Gomella, MD
  • Prostate cancer with high prostate-specific-antigen level and involvement of retroperitoneal and periaortic lymph nodes, by Leonard Gomella, MD
  • Metastatic castration-resistant prostate cancer, by Daniel Petrylak, MD

Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This second of 3 PER Pulse™ Recaps summarizing the online program focuses on interviews with Dr. Quinn, during which he discussed:

  • His approach toward a 54-year-old male with metastatic clear-cell RCC (post-nephrectomy) that progressed while receiving first-line sunitinib
  • Specific factors that might influence treatment selection for patients with metastatic clear-cell RCC (eg, pace of progression, symptoms, physician bias)
  • Potential implications of the CABOSUN trial on subsequent lines of therapy (eg, sequencing of nivolumab, other VEGFR TKIs, lenvatinib + everolimus)
  • How the potential use of adjuvant sunitinib (based on S-TRAC trial data) would affect treatment algorithms in the metastatic setting
  • Continuation of a checkpoint inhibitor for a patient with stable disease or subtle progression, and switching therapy for a patient with symptomatic progression or who is not tolerating the therapy
  • Anecdotal experiences with patients who have discontinued checkpoint inhibitor therapy after achieving a major response

3 of 3
PER Pulse™ Recap

Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies is an online educational activity that features a series of short video interviews with expert faculty, who address a variety of questions commonly faced by practicing urologists and oncologists via discussion of clinical vignettes that were presented at the live congress. The online activity features discussion on:

  • Metastatic, post-platinum urothelial cancer, by Daniel Petrylak, MD
  • Metastatic renal cell carcinoma after tyrosine kinase inhibitor failure, by David Quinn, MD, MBBS, PhD
  • Early prostate cancer, by Leonard Gomella, MD
  • Prostate cancer with high prostate-specific-antigen (PSA) level and involvement of retroperitoneal and periaortic lymph nodes, by Leonard Gomella, MD
  • Metastatic castration-resistant prostate cancer, by Daniel Petrylak, MD

Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This third of 3 PER Pulse™ Recaps summarizing the online program focuses on interviews with Dr. Gomella, during which he discussed:

  • His approach toward a 57-year-old patient with prostate cancer (perineural invasion, 2.5-cm periaortic lymph nodes, and enlarged prostate; PSA, 45 ng/mL; Gleason score, [4+5])
  • Unclear benefit of adding local or systemic therapy to standard androgen-deprivation therapy in the setting of low-volume, castration-naïve, metastatic prostate cancer
  • His approach when progression is limited to biochemical failure
  • Factors that influence his selection of an androgen-deprivation agent (eg, testosterone level, critical spinal cord lesion, impending fracture)
  • Essentials that a urologist should know about immunotherapy in genitourinary malignancies




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By